A Johnson & Johnson drug acquired as part of a $6.5 billion deal has preliminary data showing it met the main goal of a mid-stage test in a rare blood disorder that can become fatal to fetuses. Full data from the trial will be presented at a future scientific meeting.
UCB needs a stronger rare disease hand evaluate.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from evaluate.com Daily Mail and Mail on Sunday newspapers.